Other therapy.
Genomic risk classification and whole transcriptome analysis of HR+/HER2- Post-partum breast cancers โ A FLEX sub study
Publication: ESMO Breast 2024 Authors:ย Virginia F. Borges1, Elena Shagisultanova1, Read More
Other therapy.
Publication: ESMO Breast 2024 Authors:ย Virginia F. Borges1, Elena Shagisultanova1, Read More
Publication: European Journal of Cancer 217 (2025) 115222 Authors: Read More
Source: San Antonio Breast Cancer Symposiumยฎ Authors: Robert Maganini, Read More
Publication: ESMO Open - Volume 9 - Issue 11 Read More
Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Read More
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreThe Breast 76 (2024) 103752 Author: Mansani et al.
Read More: Cost consequence model of the MammaPrintยฎ (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Read MoreSSO 2024 Author: Solis-Pomales et al.
Read MoreJournal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read More